Zobrazeno 1 - 3
of 3
pro vyhledávání: '"C. F. M. Roozen"'
Autor:
Gerrit-Jan Liefers, Monique K van der Kooij, Marten Visser, Linda de Bruin, Ellen Kapiteijn, Els M E Verdegaal, Caroline E van der Minne, Pauline M Meij, Inge C F M Roozen, Mare A Jonker, Shelley van den Bosch, Frank M Speetjens
Publikováno v:
BMJ Open, Vol 10, Iss 11 (2020)
Introduction Treatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltratin
Externí odkaz:
https://doaj.org/article/7801791fed264d05be8148157a140694
Autor:
T. M. L. Tong, M. C. Burgmans, F. M. Speetjens, A. R. van Erkel, R. W. van der Meer, C. S. P. van Rijswijk, M. A. Jonker-Bos, C. F. M. Roozen, M. Sporrel-Blokland, J. Lutjeboer, E. L. van Persijn van Meerten, C. H. Martini, R. W. M. Zoethout, F. G. J. Tijl, C. U. Blank, E. Kapiteijn
Publikováno v:
CardioVascular and Interventional Radiology. 46:350-359
Autor:
Henk-Jan Guchelaar, Ellen Kapiteijn, J. den Hartigh, T. C. Schneider, D. de Wit, N. P. van Erp, J.J.M. van der Hoeven, C. F. M. Roozen, Thera P. Links, D J A R Moes, Hans Gelderblom
Publikováno v:
Cancer Chemotherapy and Pharmacology, 78(1), 63-71. SPRINGER
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 78, 1, pp. 63-71
Cancer Chemotherapy and Pharmacology, 78, 63-71
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology, 78, 1, pp. 63-71
Cancer Chemotherapy and Pharmacology, 78, 63-71
Background Everolimus is a mTOR inhibitor used for the treatment of different solid malignancies. Many patients treated with the registered fixed 10 mg dose once daily are in need of dose interruptions, reductions or treatment discontinuation due to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c8597111ab7686e94f5253885d89ae6
http://hdl.handle.net/1887/99382
http://hdl.handle.net/1887/99382